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Sinuses	 (IFI-	PS)	 are	 rare,	 life-	threatening	 infections	 in	 haematologic	 patients,	 and	
their	management	remains	a	challenge	despite	the	availability	of	new	diagnostic	tech-
niques	and	novel	antifungal	agents.	In	addition,	analyses	of	large	cohorts	of	patients	





















temporary	 cohort	of	 cases	may	allow	a	more	effective	diagnostic	 and	 therapeutic	
management	of	these	very	rare	IFI	complications	in	haematologic	patients.










outcome	of	 haematologic	 patients	with	 IFI	 involving	CNS	 and	PS,	
and	 therefore,	 the	 most	 appropriate	 diagnostic	 and	 therapeutic	
approach	remain	to	be	clearly	defined.	In	fact,	in	the	literature,	we	
found	only	case	reports	or	small	retrospective	studies,	more	often	
not recent.1,9-13	 The	 most	 frequently	 reported	 pathogens	 were	
moulds	 and	 especially	Aspergillus	 and	Mucormycetes.1,2,6,14,15	 The	
therapeutic	 management	 of	 these	 infectious	 complications	 is	 still	
very	complex	and	heterogeneous,	and	recent	studies	on	the	efficacy	
of	new	antimycotic	drugs	are	limited	so	that	there	is	no	clear	stan-
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The	 patients’	 privacy	 was	 preserved	 and	 each	 haematological	
centre	 reported	 an	 identifying	 code	 for	 each	 case.	All	 the	 centres	
involved	performed	 the	similar	diagnostic	workup	 including	micro-
biological	 [i.e,	 research	 of	 indirect	 biomarkers:	 serum	 β-	D-	Glucan,	
Galactomannan	(GM)	on	blood,	cerebrospinal	fluid	or	other	sites]	and	
radiological	investigations	(i.e,	computerised	tomography	[CT]	and/






steroid	 therapy,	 diabetes,	 previous	history	of	 IFI,	 chemotherapy	 in	
the	previous	30	days,	type	and	length	of	antifungal	prophylaxis);	the	





Severe	 neutropenia	 was	 defined	 as	 a	 number	 of	 granulocytes	
(PMN)	 ≤500/mmc.	 Mild/moderate	 neutropenia	 was	 defined	 as	











Complete	 or	 partial	 response	 (CR,	 PR)	 to	 therapy	was	 defined	
based	 on	 clinical,	 radiologic	 and/or	 mycological	 data	 as	 by	 the	
EORTC/MSG	 consensus	 group.	 Overall	 Response	 rate	 (ORR)	 was	
defined	as	CR+PR.16
In	 the	 case	of	 a	 patient’s	 death,	 the	 cause	of	 death	 had	 to	 be	
specified	as	one	of	 the	 following:	 (a)	mycosis	as	primary	cause,	 (b)	
haematological	 disease	 as	 primary	 cause	with	 concomitant	myco-






Descriptive	 statistics	 (including	 mean,	 standard	 deviation,	 me-
dian,	 range,	 frequency,	 percentages)	 were	 calculated	 to	 analyse	
and	compare	the	study	cohorts.	Overall	survival	 (OS)	 (defined	as	
the	interval	between	the	date	of	IFI	diagnosis	and	the	date	of	last	
follow-	up	or	 death)	was	 estimated	by	 the	Kaplan–Meier	 survival	





are	presented	 to	 assess	 the	precision	of	 the	 estimates	obtained.	
All	P-	values	are	 two-	sided,	with	statistical	 significance	evaluated	
at	 the	0.05	 alpha	 level.	 Fisher’s	 exact	 test	was	 used	 to	 compare	





During	 the	 study	period,	 89	 cases	 of	 Proven	 (53	 cases)	 or	 Probable	
(36	 cases)	 IFI	with	 localisation	 to	 the	CNS	and	PS	were	 recorded	 in	
34	Haematological	centres.	The	median	age	of	patients	was	40	years	
(range	 5-	79).	 The	 study	 population	 included	 23	 (26%)	 paediatric	 pa-
tients	(age	≤18	years).	The	demographic	characteristics	of	patients	and	




most	of	 the	CNS/PS	 IFI	has	been	documented	 in	patients	with	an	
active	haematological	disease	(81%)	and	specifically	at	the	onset	of	
disease	(31/89,	35%)	or	during	its	relapse	(41/89,	46%).	Twenty-	nine	













(48%)	 focal	 neurological	 symptoms	 (i.e,	 aphasia,	 dysarthria,	 diplo-
pia)	have	been	 reported,	with	or	without	a	concomitant	alteration	
of	 consciousness.	 Neurological	 disorders	 were	 significantly	 more	







Fusarium spp.	 and	 in	 1	 case	 Scedosporium	 apiospermum	 (Table	1).	








All IFI- CNS IFI- PS P value
Patients	and	haematologic	disease
N°	of	cases 89 71 18
Age	mean	±	SD 39	±	22 37	±	22 46.6	±	19.4
median	(range) 40	(5-	79) 36	(5-	74) 47.5	(12-	79)
Haematologic	disease
AML 30	(34%) 22	(31%) 8	(44%) 0.4
ALL 31	(35%) 28	(39%) 3	(17%) 0.09
Chronic leukaemia 11	(12%) 9	(13%) 2	(11%) 0.9
MDS 4	(4%) 2	(3%) 2	(11%) 0.2
Aplasia 4	(4%) 5	(7%) 1	(6%) 0.9
NHL 6	(7%) 4/71	(6%) 2	(11%) 0.6
MM 1/71	(1%)
Disease	phase
Onset 31	(35%) 24	(33%) 7	(39%) 0.8
Relapse/refractory 41	(46%) 33	(46%) 8	(44%) 0.9
Consolidation 17	(19%) 14	(20%) 3	(17%) 0.9
PMN	<	500	at	onset	of	infection 44	(49%) 31/71	(44%) 13	(72%) 0.0037
Previous	Allo-	SCT 26/89	(29%) 24/71	(34%) 2/18	(11%) 0.08
IFI	characteristics
N°	of	cases 89 71 18
Proven 53	(60%) 38/71	(25%) 15/18	(83%) 0.03
Probable 36	(40%) 33/71	(46%) 3/18	(17%)
Presenting	symptoms
Headache 23	(26%) 20	(28%) 3	(17%)
Seizure 16	(18%) 16	(23%) 0
Fever 58	(65%) 46	(65%) 12	(67%)
Neurological	symptoms 43	(48%) 40	(56%) 3	(17%) 0.04
rhinorrhea 8	(9%) 3	(4%) 5	(28%)
Aetiology
Aspergillus spp. 61	(70%) 49	(69%) 12	(67%) 0.9
Mucorales 20	(22%) 15	(21%) 5	(28%) 0.5
Fusarium spp. 2	(2%) 1	(1%) 1	(6%)
Cryptococcus spp. 4	(4%) 4	(6%) 0
Trichosporum sp. 1	(1%) 1	(1%) 0
Scedosporium sp. 1	(1%) 1	(1%) 0
Isolate	IFI 27	(30%) 18	(25%) 9	(50%) 0.05
Disseminated	IFI 62	(70%) 53	(75%) 9	(50%) 0.05
AML,	acute	myeloid	leukaemia;	ALL,	acute	lymphoid	leukaemia;	MDS,	myelodysplastic	syndrome,	MM,	multiple	myeloma.








with	 significant	prevalence	 in	 the	 cohort	of	 IFI-	CNS	 (53/71	cases-
























GM test on CSF 30/71	(42%)
Positive	GM	test	on	CSF 20/30	(67%)









ALL IFI- CNS IFI- PS P value
N°	of	cases 89 71 18
Drug	therapy 84	(94%) 66	(93%) 18	(100%) 0.57
Line	of	therapy
1td 35	(42%) 30	(45%) 5	(28%)
≥2	td 49	(58%) 36	(55%) 13	(72%) 0.28
Combination therapy 32	(38%) 21	(32%) 11	(61%) 0.03
Length	of	therapy
mean	±	SD 122	±	168 131,8	±	185 85,9	±	70









ORR 48	(57%) 36	(54%) 12	(67%) 0.57
CR 29	(34%) 22	(33%) 7	(39%) 0.78
PR 19	(23%) 14	(21%) 5	(28%) 0.54
NR 36	(43%) 30	(46%) 6	(33%) 0.4
Outcome
Alive 28	(31%) 23	(32%) 5	(28%) 0.77
Deaths 61	(69%) 48	(68%) 13	(72%)
Attributable	mortality 20/61	(33%) 14/48	(29%) 6/13	(46%) 0.32
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onset	of	 IFI.	 In	detail,	28/55	received	Fluconazole	 (FLUCO),	14/55	
Posaconazole	 (POSA),	 5/55	 Itraconazole	 (ITRA),	 3/55	 liposomal	
Amphotericin	B	(AMB),	3/55	Voriconazole	(VORI),	1/55	Caspofungin	
(CASPO)	 and	 1/55	 Micafungin.	 The	 mean	 duration	 of	 antifungal	





Table	3	 shows	 the	antifungal	 therapy	administered	 to	84/89	pa-



















more	 often	 in	 patients	with	 IFI-	PS	 (33%)	 as	 compared	 to	 IFI-	CNS	
(10%)	(P	=	0.028).
The	 overall	 response	 rate	 (ORR)	 to	 treatment	 was	 57%	 (with	
CR	 34%	 and	 PR	 23%),	 without	 significant	 differences	 between	
F IGURE  1  (A)	Overall	Survival	from	
IFI	Diagnosis—All	Cases.	(B)	OS	from	IFI	
Diagnosis—according	to	site	(CNS	or	PS)
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tail,	 the	 following	 variables	 were	 checked	 and	 compared:	 isolated	
IFI-	CNS	vs	non-	isolated	forms,	proven	vs	probable	IFI,	Aspergillosis	
vs	other	aetiological	agents,	PMNs	lower	or	higher	than	500	at	the	






















Unfortunately,	 recent	epidemiological	studies	 involving	 large	co-
horts	of	haematological	patients	with	IFI-	CNS	or	IFI-	PS	are	lacking	and,	
TABLE  4 Univariate	and	multivariate	analyses	of	factors	that	influenced	overall	survival	in	66	cases	of	IFI-	CNS	who	received	treatment




0.317 0.048 1.869 1.0072-	3.4681
Response	to	antifungal	therapy	(CR/PR	vs	NR) 0.3583 <0.0001 10.2201 5.0814-	20.5557
Proven	vs	probable	IFI 0.3049 0.338 0.7468 0.4121-	1.3534
Causative	agent	(Aspergillus	vs	Others) 0.3192 0.826 1.0725 0.5756-	1.9983
Isolated	IFI-	CNS	vs	non-	isolated	forms 0.3418 0.403 0.752 0.3862-	1.4643
Age	at	IFI-	CNS	diagnosis	(<	or	>	65	y) 0.3922 0.1564 1.7434 0.8114-	3.7457
PMN	(<	or	>	500/mmc) 0.3035 0.849 1.0591 0.5860-	1.9143
Allo-	SCT	(yes	or	not) 0.3156 0.195 0.6646 0.3591-	1.2298
Surgical	resection	(yes	or	not) 0.3618 0.26 1.503 0.7423-	3.0434




0.3925 0.0165 2.5618 1.1916-	5.5076
Response	to	antifungal	therapy	(CR/PR	vs	NR) 0.4313 ≤0.0001 15.3755 6.6310-	35.6520
Proven	vs	probable	IFI 0.4848 0.7513 0.8575 0.3332-	2.2072
Causative	agent	(Aspergillus	vs	Others) 0.5498 0.4177 1.5613 0.5345-	4.5609
Isolated	IFI-	CNS	vs	non-	isolated	forms 0.3841 0.409 1.3732 0.6493-	2.9043
Age	at	IFI-	CNS	diagnosis	(<	or	>	65	y) 0.5183 0.7727 0.8609 0.3134-	2.3654
PMN	(<	or	>	500/mmc) 0.3463 0.0825 1.8246 0.9287-	3.5848
Allo-	SCT	(yes	or	not) 0.3777 0.485 1.3018 0.6232-	2.7191
Surgical	resection	(yes	or	not) 0.4996 0.3171 1.6485 0.6222-	4.3674
Combination	antifungal	therapy	(yes	or	not) 0.493 0.8426 1.1029 0.4217-	2.8844
HD,	haematologic	disease;	Allo-	SCT,	allogeneic	stem	cell	transplant;	PMN,	granulocytes.
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therefore,	there	are	no	established	diagnostic-	therapeutic	approaches	


































































Unfortunately,	 the	 median	 OS	 of	 treated	 cases	 was	 short	
(3.5	months)	with	a	12-	month	OS	of	32%.	Sixty-	nine	per	cent	(61/89)	
of	 patients	 died,	 but	 it	 should	 be	 emphasised	 that	many	patients	







to	affect	OS	are	 the	 response	 (CR	or	PR)	 to	antifungal	 treatment	
and	the	status	of	haematologic	disease	(not	in	an	advanced	stage).




However,	 compared	 to	older	epidemiological	data,	 there	 is	 a	 sub-
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